Clinical trial · Interventional
Exercise and Colon Cancer
The COURAGE Trial: Colon Recurrence and Aerobic Exercise: A Feasibility Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Despite the success of surgery and chemotherapy among people with colon cancer, 30-50% of patients develop recurrent disease. Physical activity has emerged as a potential lifestyle intervention to reduce cancer recurrence and improve survival among people with colon cancer (CC). This pilot study aims to identify the dose-response effects of aerobic exercise on molecular and cellular pathways associated with physical activity and CC outcomes among patients with stage II and III CC.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Stage II Colon Cancer | Malignant Colon Neoplasm | CURATED_BROADER | 0.78 |
| Stage III Colon Cancer | Malignant Colon Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Exercise | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- exercise
- description
- aerobic exercise on soluble intercellular adhesion molecules
- interventionNames
- Other: Exercise
Primary outcomes (1)
- measure
- 1. The biological efficacy of aerobic exercise on soluble intercellular adhesion molecule-1 (sICAM-1), and soluble vascular adhesion molecule-1 (sVCAM-1) prognostic biomarkers.
- timeFrame
- 2 years
Secondary outcomes (4)
- measure
- Exercise adherence, quantified as the percentage of total dose completed relative to the total dose prescribed during the six-month study;
- timeFrame
- 6 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. histologically confirmed TNM stage II-III CC; 2. completed surgical resection and adjuvant chemotherapy (if applicable) within 1-24 months before entering the study; 3. ≤120 min/wk of self-reported moderate or vigorous intensity physical activity using the Paffenbarger physical activity questionnaire; 4. age ≥18 years; 5. written physician approval; 6. no additional surgery planned within the 6-month intervention (including colostomy reversal); 7. ability to walk unaided for 6-minutes; 8. no contraindications to exercise using the PA readiness questionnaire (PAR-Q), unless physician approves participation with specific knowledge of this contraindication. Exclusion Criteria: 1. history of another primary invasive cancer (other than non-melanoma skin-cancer); 2. evidence of metastatic CC (i.e., TNM M1); 3. planning to receive any additional adjuvant chemotherapy; 4. pregnant or breast feeding; 5. unable to provide baseline blood sample; 6. cardiac conditions, including the following: 1. myocardial infarction or coronary revascularization procedure within prior 3 months; 2. uncontrolled hypertension (systolic ≥180 mmHg or diastolic ≥100 mmHg); 3. high-risk or uncontrolled arrhythmias; 4. clinically significant valvular disease; 5. decompensated heart failure; 6. known aortic aneurysm; 7. any other condition that may impede testing of the study hypothesis or make it unsafe to engage in the exercise program (determined by the investigative team).
References
Publications (1)
- DERIVEDBrown JC, Compton SLE, Meyerhardt JA, Spielmann G, Yang S. The dose-response effect of aerobic exercise on inflammation in colon cancer survivors. Front Oncol. 2023 Dec 12;13:1257767. doi: 10.3389/fonc.2023.1257767. eCollection 2023. PMID 38148846